EB 1089, a novel vitamin D Analog with strong antiproliferative and differentiation-inducing effects on target cells

This publication has 37 references indexed in Scilit:

• Inhibition of insulin- and insulin-like growth factor-I-stimulated growth of human breast cancer cells by 1,25-dihydroxyvitamin D3 and the vitamin D3 analogue EB1089
  European Journal Of Cancer, 1996
• Comparative effects of 1,25-dihydroxyvitamin D3 and EB 1089 on mouse renal and intestinal 25-hydroxyvitamin D3-24-hydroxylase
  Journal of Bone and Mineral Research, 1995
• Studies on two new vitamin D analogs, EB 1089 and KH 1060: Effects on bone resorption and osteoclast recruitment in vitro
  Bone, 1995
• Vitamin D and breast cancer: the therapeutic potential of new vitamin D analogues
  Endocrine-Related Cancer, 1995
• VITAMIN D DERIVATIVES IN COMBINATION WITH 9-cis RETINOIC ACID PROMOTE ACTIVE CELL DEATH IN BREAST CANCER CELLS
  Journal of Molecular Endocrinology, 1995
• Steroid Hormone Modulation of Vitamin D Receptor Levels in Human MG-63 Osteosarcoma Cells
  Biochemical and Biophysical Research Communications, 1994
• The 1,25-dihydroxyvitamin D3 (VD) analogues MC903, EB1089 and KH1060 activate the VD receptor: Homodimers show higher ligand sensitivity than heterodimers with retinoid X receptors
  The Journal of Steroid Biochemistry and Molecular Biology, 1994
• 1α,25-Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cellsin vitro
  Clinical & Experimental Metastasis, 1994
• Murine osteoblast interleukin 4 receptor expression: Upregulation by 1,25 dihydroxyvitamin D₃
  Journal of Cellular Biochemistry, 1993
• Retinoic acid modulation of 1,25(OH)2 vitamin D3 receptors and bioresponse in bone cells: Species differences between rat and mouse
  Biochemical and Biophysical Research Communications, 1985